| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
No specific biological target is associated with sodium dihydrogen phosphate monohydrate, as it functions primarily as a buffer and source of phosphate ions rather than a direct pharmacological agent. However, phosphate ions are essential for many biological processes, including energy transfer (ATP), nucleic acid synthesis (DNA and RNA), and cellular signaling (phosphorylation). The compound's role in maintaining pH is critical for the proper functioning of enzymes and other biological molecules. In drug delivery systems, the compound is used to achieve in situ amorphisation, enhancing drug solubility and bioavailability. Its ability to act as a source of phosphate ions may also influence mineral metabolism and bone health, but these effects are indirect and related to its role as a source of phosphate rather than a specific pharmacological target.
|
|---|---|
| ln Vitro |
In vitro, sodium dihydrogen phosphate monohydrate is commonly used for buffer preparation. It is used in the development of multiparticulate drug delivery systems for in situ amorphisation, enhancing drug solubility and bioavailability. It is used for liquid chromatography and molecular biology applications. The compound is tested for DNase, RNase, and protease activity, with no detectable activity. In biochemical research, it is used to maintain pH in enzyme assays, protein purification, and cell culture media. Its acidic properties make it useful in maintaining pH levels in various formulations. It is a widely used buffer in biological and biochemical research.
|
| ln Vivo |
In vivo, sodium dihydrogen phosphate monohydrate is not typically administered as a drug. However, it may be used in drug delivery systems to enhance drug solubility and bioavailability. The compound's phosphate ions are essential for many biological processes, and its use as a source of phosphate may have nutritional or therapeutic implications. However, specific in vivo studies on the compound as a therapeutic agent are not documented.
|
| Enzyme Assay |
Cell-free assays for sodium dihydrogen phosphate monohydrate involve its use as a buffer. The compound is dissolved in water to prepare buffer solutions at desired pH values. The buffer is used in various biochemical assays, including enzyme assays, protein purification, and nucleic acid manipulation. Its pH is adjusted by titration with sodium hydroxide or phosphoric acid. The compound's ability to maintain pH is assessed by measuring the pH of the buffer solution under various conditions. Its use in drug delivery systems involves studying its ability to enhance drug solubility and bioavailability.
|
| Cell Assay |
Cellular assays for sodium dihydrogen phosphate monohydrate involve its use as a buffer in cell culture media. The compound is used to maintain physiological pH in cell culture, and cell viability and function are evaluated in the presence of the buffer. The compound's compatibility with cell growth and function is assessed. In drug delivery studies, cells are treated with drug formulations containing the compound, and drug uptake and efficacy are evaluated. The compound itself is not typically used as a test article in cellular assays beyond its role as a buffer component.
|
| Animal Protocol |
Animal studies for sodium dihydrogen phosphate monohydrate are not typically conducted, as the compound is primarily a buffer and not a pharmacological agent. However, it may be used in drug delivery systems that are evaluated in animal models. In these studies, drug formulations containing the compound are administered to animals, and drug pharmacokinetics and efficacy are assessed. The compound's safety and biocompatibility are evaluated as part of the formulation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for sodium dihydrogen phosphate monohydrate are not applicable, as the compound is primarily a buffer and source of phosphate ions rather than a drug. Phosphate ions are essential nutrients that are absorbed from the diet and distributed throughout the body. The compound's use in drug delivery systems may influence the pharmacokinetics of the drug by enhancing its solubility and bioavailability. However, comprehensive pharmacokinetic studies on the compound itself are not performed, as it is not intended for therapeutic use.
|
| Toxicity/Toxicokinetics |
Toxicological data for sodium dihydrogen phosphate monohydrate indicate that it is generally recognized as safe for its intended uses. It is commonly used in food, pharmaceutical, and research applications. The compound is tested for DNase, RNase, and protease activity, with no detectable activity. Standard safety precautions for handling inorganic salts apply, including the use of personal protective equipment such as gloves and safety goggles. The compound should be handled in a well-ventilated area, and contact with skin and eyes should be avoided. In case of exposure, affected areas should be rinsed thoroughly with water.
|
| References |
[1]. Buur JL, et al. Analysis of diltiazem in Lipoderm transdermal gel using reversed-phase high-performance liquid chromatography applied to homogenization and stability studies. J Pharm Biomed Anal. 2005;38(1):60-65.
|
| Additional Infomation |
Sodium dihydrogen phosphate monohydrate is the monohydrate form of sodium dihydrogen phosphate. It contains sodium dihydrogen phosphate.
4,4-Dimethylcyclohexanone is a research chemical, not a drug. It has no clinical trial or marketing approval status for therapeutic use. The compound is an inorganic salt commonly used for buffer preparation. It is characterized by its ability to act as a source of phosphate ions, which are essential for many biological processes. It exhibits acidic properties due to the presence of dihydrogen phosphate ions, making it useful in maintaining pH levels in various formulations. It is a widely used buffer in biological and biochemical research. The compound is also used in the development of multiparticulate drug delivery systems for in situ amorphisation, enhancing drug solubility and bioavailability. It is used for liquid chromatography and molecular biology applications. It is supplied with a purity of ≥99% and should be stored in a cool, dry place. |
| Molecular Formula |
H4NAO5P
|
|---|---|
| Molecular Weight |
137.99
|
| Exact Mass |
137.969
|
| CAS # |
10049-21-5
|
| Related CAS # |
Anhydrous sodium dihydrogen phosphate;7558-80-7;Phosphoric acid (sodium hydrate),≥99.0%;13472-35-0
|
| PubChem CID |
516949
|
| Appearance |
White to off-white solid powder
|
| Density |
2.04 g/cm3
|
| Boiling Point |
158ºC at 760mmHg
|
| Melting Point |
60℃
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
0
|
| Heavy Atom Count |
7
|
| Complexity |
61.9
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
P(=O)(O[H])(O[H])[O-].[Na+].O([H])[H]
|
| InChi Key |
BBMHARZCALWXSL-UHFFFAOYSA-M
|
| InChi Code |
InChI=1S/Na.H3O4P.H2O/c;1-5(2,3)4;/h;(H3,1,2,3,4);1H2/q+1;;/p-1
|
| Chemical Name |
sodium;dihydrogen phosphate;hydrate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 100 mg/mL (724.69 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.2469 mL | 36.2345 mL | 72.4690 mL | |
| 5 mM | 1.4494 mL | 7.2469 mL | 14.4938 mL | |
| 10 mM | 0.7247 mL | 3.6235 mL | 7.2469 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
